Current Atherosclerosis Reports

Papers
(The H4-Index of Current Atherosclerosis Reports is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Revascularization Options for Left Main Disease: What Clinicians Need to Know157
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions144
Polysocial Risk Scores: Implications for Cardiovascular Disease Risk Assessment and Management115
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes113
Whether and Why Do We Need a Vaccine Against Atherosclerosis? Can We Expect It Anytime Soon?99
The Greatly Under-Represented Role of Smooth Muscle Cells in Atherosclerosis79
A Narrative Review of the Association Between Depression and Heart Disease Among Women: Prevalence, Mechanisms of Action, and Treatment78
PCSK9 Inhibition and Risk of Diabetes: Should We Worry?67
The Effects of FABP4 on Cardiovascular Disease in the Aging Population67
Anti-apoC-III Therapies and Implications for Treatment of Pancreatitis and Cardiovascular Disease66
The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments65
Salutary Effects of Nutritional Ketosis for the Diseased Human Heart57
Polypharmacy and Cardiovascular Diseases: Consideration for Older Adults and Women56
From ‘Omics to Multi-omics Technologies: the Discovery of Novel Causal Mediators51
Genetic Testing for Familial Hypercholesterolemia in Clinical Practice51
Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond43
Effects of Pioglitazone On Lipoprotein(a): A Meta-analysis43
Spontaneous Coronary Artery Dissection (SCAD): Unveiling the Enigma of the Unexpected Coronary Event41
The Intersection Between COVID-19, Cardiovascular Disease, and Diet: a Review41
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease38
Nutrition Interventions for Youth with Dyslipidemia: Who, What, When, and Where?38
Inflammation in the Peri-ACS Period: Ready for Prime Time?37
The Emerging Specialty of Cardio-Rheumatology36
GLP-1 Receptor Agonists and Cardiovascular Disease: What Do Clinicians Need to Know?35
Percutaneous Coronary Interventions in Women35
The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention34
Lipoprotein(a): from Causality to Treatment32
Lipid Lowering Therapy Utilization and Lipid Goal Attainment in Women31
Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease31
Myeloid Cells in Abdominal Aortic Aneurysm30
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?30
0.33814692497253